Adis JournalsOverview

The Adis publishing heritageThe Adis Journals brand has evolved over

40 years to become synonymous with

current, comprehensive and objective

journal publishing, with a strong specialism

in pharmacology and pharmacotherapy.

Adis has proved that acute customer focus

can be achieved without compromising

the highest ethical publishing standards,

including rigorous independent peer

review. Adis Journals endorses the ICMJE

guidelines and is a member of COPE,

observing their Code of Conduct and Best

Practice Guidelines for Journal Editors.

Publishing research at every stage of the drug lifecycleCovering all aspects of the drug development

continuum from bench to bedside, Adis

Journals are a unique must-have resource for

researchers, clinicians, clinical pharmacists,

clinical pharmacologists, teachers, students,

and anyone with an interest in drug therapy

and pharmacology.

The Adis portfolio offers a wide range of

specialist titles publishing a complementary

blend of original research, independent

Adis Drug Evaluations and invited reviews.

Adis Editors possess great insight into the

trends within their speciality areas, and are

committed to recognizing and meeting the

needs of their readership.

Most Adis journals are indexed in MEDLINE

and have an international following of

paid subscribers.

Key features The following elements of the Adis Journals

program have been refined over 4 decades:

Strong customer service ethic

Adis’ publishing team takes great pride in the

speed and quality of the customer service they

provide. With offices in every major market

around the world, there is always a local Adis

representative available to provide a local

language service.

Cascading peer review

If a submitted article is rejected by an Adis

journal Editor based on peer-review comments,

those comments can be passed on to the Editor

of another relevant Adis journal and further

peer review may not be necessary.

Adis Open Access

9 An option to publish

any submitted original

research article under

an open access license

9 Available for any Adis

journal that publishes

original research articles

9 Articles are peer reviewed and must meet

the journal’s usual acceptance criteria

9 Journal Editors are blinded to the open

access status of papers so that there is

no influence on editorial decisions

9 Authors pay an Article Processing Charge

(APC) of US$3,000 upon acceptance

9 Open access articles are then published

online-only, and are freely available on

AdisOnline.com and Ovid to read, copy,

share and distribute for non-commercial

purposes

Adis Rapid

Publishing

Service

9 An optional service for

any submitted original

research article

9 7-10 working days peer review guaranteed

9 Publish in a choice of well-established

journals in as little as 3-4 weeks

9 Rigorous assessment by Editors and

external peer reviewers

9 Small fee to cover fast-track

administration costs

Adis Drug Evaluations

& Drug Profiles

9 Comprehensive

single-agent reviews,

highlighting the unique

clinical benefits of

a drug

9 Independently researched and expertly

written by skilled Adis writers

9 Peer reviewed externally by therapy

area experts

9 Written to country-specific labelling

where appropriate

9 Timed to maximize clinical relevance and

topicality for the healthcare community

9 Remind healthcare professionals of the

wealth of best evidence supporting a

product’s place in therapy

Introduction Life after publication AdisOnline.com

9 Articles published in Adis journals

appear on AdisOnline.com, a modern

well-established journal platform

with high volumes of traffic

9 Adis articles are also

distributed on Ovid and

through many other aggregation

and document delivery platforms

9 AdisOnline is optimized for a perfect

viewing experience on most mobile

devices

9 Articles on AdisOnline are available:

- In HTML and PDF versions

- In EPUB version for e-reader devices

such as iPad

- With a facility to export tables and

figures to PowerPoint

- With hyperlinks to referenced articles

- In URL formats that are easily located

by search engines and library systems

- With a facility to attach Supplementary

Digital Content to the article which

could be as simple as an appendix of

data tables, or as complex as a video

or podcast (e.g. author commentary)

Article usage reports

These reports are available on request after

an article is published on AdisOnline. They use

WebTrends data to show the number of times

an article has been viewed since publication.

They also provide a ranking of those article

views versus all the other articles viewed in

that journal during the same period.

Digital eprints

Adis uses the latest digital book technology

and digital rights management, providing

flexible eprint solutions with ROI metrics

to meet a wide range of communication

objectives.

� �

General Medicine

Drugs

Premier journal,

publishing pivotal

phase 3 research

and seminal reviews

CDI

Ideal vehicle for

supporting studies

Drugs in R&D

A fully open access

journal for supporting

research and reviews

PharmacoEconomics

Premier health

economics journal

Applied Health Economics

and Health Policy

Sister journal to

PharmacoEconomics

with a broader scope

The Patient:

Publishes studies of

patient preferences and

patient-centered outcomes

Health Outcomes

Pediatric Drugs

Rapid journal publication

is becoming increasingly

important with European

requirements to post

pediatric study results in

EudraCT database within

6 months of completion

Drugs & Aging

Increasingly important

area as older population

grows

Special Patient Populations

Cardiology, CNS, and DermatologyA strong presence in selected

therapy areas

Special DisciplinesIndustry-leading titles in key areas

of drug development

Therapy area strengths

� �

Permissions required to reproduce

or adapt material

Authors must acknowledge and seek

the appropriate permissions to use all

text, illustrations, and tables adapted or

reproduced from other publications.

Duplicate publication and

duplicate submission

Manuscripts are considered with the

understanding that they have not been

published previously and are not under

consideration by another publication.

Clinical trial registration

With the exception of Clinical Drug

Investigation all Adis journals require,

as a condition of consideration of original

clinical research for publication, prospective

registration of clinical trials in a public

trials registry before recruitment of any

participants. This applies to trials which

commenced after 1 July 2005: for older trials

retrospective registration will be acceptable,

but only if completed before submission of

the manuscript to the journal.

Copyright

Unless their article is published under an

open access license, authors will be asked

to sign a transfer of copyright agreement,

which recognizes the common interest that

both the journal and author(s) have in the

protection of copyright.

Authorship criteria

Each author should have participated

sufficiently in the submitted work to take

public responsibility for appropriate portions

of the content. Authors should meet all the

following criteria:

9 Conceived and planned the work that

led to the manuscript, and/or played an

important role in the acquisition, analysis,

and interpretation of the data

9 Wrote the paper and/or made substantive

suggestions for revision

9 Approved the final submitted version

The corresponding author takes responsibility

for the work as a whole, from inception to the

published manuscript, and will be responsible

for sign-off of the final proofs prior to

publication.

The corresponding author must provide a

statement indicating the names and

contributions of all persons who have provided

input to the manuscript, but who do not fulfil

authorship criteria. This information will be

published in an Acknowledgments section

of the paper.

Authors should obtain written permission

from individuals to be named in the

Acknowledgments section.

Conflict of Interest Statement for authors

and role of the funding source

To prevent ambiguity, authors must state

explicitly whether potential conflicts do or

do not exist. Both conflicts and the role of

any funding source must be summarized in

the Acknowledgments section of the paper.

Ethical conduct of research

For human or animal experimental

investigations, appropriate institutional

review board approval is required, and/or

the principles Declaration of Helsinki should

be followed.

Protection of patients’ rights to privacy

Identifying information should not be

included in written descriptions, photographs,

and pedigrees unless the information is

essential for scientific purposes and the

patient gives written informed consent

for publication.

Use of personal communications and

unpublished data

Authors must include a signed statement

of permission from each individual

identified as a source of information in a

personal communication or as a source for

unpublished data.

Best publishing practice

Adis Journals is committed to the best ethical

publishing practices, endorsing the ‘Uniform

Requirements for Manuscripts Submitted

to Biomedical Journals’ developed by the

International Committee for Medical Journal

Editors (ICMJE), and is also a member of the

Committee on Publication Ethics (COPE),

observing their Code of Conduct and Best

Practice Guidelines for Journal Editors.

The full Adis policies for each journal are

available for review on AdisOnline.

The key requirements for authors are

as follows:

� �

USA

North America and East Coast

Garrett R. Groesbeck

Tel: +1 ��� ��� 91�1

Email: garrett.groesbeck@springer.com

North America, Midwest and West Coast

Philip E. Thoman

Tel: +1 ��� ��1 8���

Email: philip.thoman@springer.com

Contact usTo view Adis journals online go to:

http://adisonline.com

For more information please contact

your local representative, or alternatively:

Europe and Rest of World

Jan Seal-Roberts

Tel: +�� �0� 981 0���

Email: jan.roberts@springer.com